secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001829126-25-004450
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc Technologies appoints Dr. Josh Neman as Chief Clinical Officer
--------------------------------------------------------------------

- Dr. Josh Neman, PhD, appointed CCO; formerly Associate Professor at USC Keck School and Scientific Director of USC Brain Tumor Center.
- He will lead clinical strategy for four trials, including NEO100 approaching Phase 2a completion with full enrollment ahead of schedule.
- Neman's research on tumor-neuron interactions and GABAergic signaling supports FDA approval path and AI/quantum computing integration.
- Appointment aims to accelerate precision therapies for CNS cancers; NeOnc holds 176 patents worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625004450/0001829126-25-004450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625004450/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-004450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer